Abstract
Adriamycin is an active drug of pronounced clinical interest. It has demonstrated broad spectrum activity against a variety of tumors in man and it is a drug of particular interest since it has demonstrated definitive activity against solid tumors, including lung tumors and sarcomas which are ordinarily not too amenable to therapy with the known antitumor agents. There are currently four anthracyclines of clinical interest, namely adriamycin, daunomycin, rubidazone and carminomycin. These are compounds that are closely related structurally and all four are active in a variety of experimental tumor systems. Adriamycin and daunomycin are very closely related, the former having a hydroxyl group instead of a hydrogen in the acetyl radical of the aglycone moeity (1–3). Rubidazone is a daunomycin derivative having a benzoyl hydrazone substituent at the 13 position (4). Carminomycin differs from daunomycin in stereochemical configuration in the A ring and in having a hydroxyl group rather than methoxyl at the 4 position (5).
Based on studies presented at the International Symposium on Adriamycin, Brussels, May 16–18, 1974.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
DI MARCO, A., GAETANI, M. and SCARPINATO, B.: Adriamycin (NSC 123127) A new antibiotic with antitumor activity. Cancer Chem. Rep. 53, 33–37, 1969.
ARCAMONE, F., CASSINELLI, G., FANTINI, G., GREIN, A., OREZZI, P., POL, C. and SPALLA, C.: Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from s. peucetius var. caesius. Biotechn. Bioengin. 11:1101, 1969.
GOLDIN, A. and JOHNSON, R.K.: Antitumor effects of adriamycin and related drugs, and combination chemotherapy. Adriamycin Review, European Press-Medikon (In press).
MARAL, R., PONSINET, G. and JOLLES, G.: Etude de l’activité antitumorale expérimentale d’un nouvel antibiotique semi-synthétique: la rubidazone (22 050 R.P.) C. R. Acad. Sc. Paris 275, 301–304, 1972.
GAUZE, G.F., SVETCHNIKOVA, M.A. and UKHOLINA, R.S.: Antibiotica 18, No.8 291–292, 1973.
MIYAKAWA, A., PADARATHSINGH, M., VADLAMUDI, S. and GOLDIN, A.: E.ffect of combination treatment with adriamycin and methotrexate on the survival time of leukemic (L1210) mice. Chemotherapy 19, 38–46, 1973.
GOLDIN, A.: Some factors influencing the chemotherapeutic effectiveness of adriamycin. In International Symposium on Adriamycin, Springer-Verlag Berlin-Heidelberg-New York, pgs. 64–74, 1972.
Includes SCHABEL, F.M., Jr., Unpublished observations and Kline, I. unpublished observations.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1975 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Goldin, A., Johnson, R.K. (1975). Adriamycin Activity in Experimental Tumors. In: Ghione, M., Fetzer, J., Maier, H. (eds) Ergebnisse der Adriamycin-Therapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-66027-6_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-66027-6_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-66028-3
Online ISBN: 978-3-642-66027-6
eBook Packages: Springer Book Archive